In this episode, Michael and Josh investigate Lung Oncology research presented at ASCO 23, specifically early lung cancer treatment. They discuss Perioperative Toripalimab, LAG3 inhibitor Relatlimab and the new novel agent BI 764532, a novel DLL3-targeting T cell engaged.
Studies:
NEOTORCH: https://ascopubs.org/doi/abs/10.1200/JCO.2023.41.36_suppl.425126
NEOPREDICT: https://ascopubs.org/doi/abs/10.1200/JCO.2023.41.16_suppl.8500
DLL3-positive SCLC: https://ascopubs.org/doi/abs/10.1200/JCO.2023.41.16_suppl.8502
Many thanks to Merck for supporting this episode. Merck provided virtual access to ASCO 2023 but did not review or approve any part of OftiM's coverage of ASCO.
For more episodes, resources and blog posts, visit www.inquisitiveonc.com
Find us on Twitter @InquisitiveOnc!
If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.com
Art courtesy of Taryn Silver
Music courtesy of Music Unlimited: https://pixabay.com/users/music_unlimited-27600023/
Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.
","author_name":"Michael Fernando and Josh Hurwitz"}